A small-molecule antagonist of HIF2α is efficacious in preclinical models of renal cell carcinoma

Cancer Research

Volumn 76, Issue 18, 2016, Pages 5491-5500

  Wallace, Eli M ^a   Rizzi, James P ^a   Han, Guangzhou ^a   Wehn, Paul M ^a   Cao, Zhaodan ^a   Du, Xinlin ^a   Cheng, Tzuling ^a   Czerwinski, Robert M ^a   Dixon, Darryl D ^a,b   Goggin, Barry S ^a   Grina, Jonas A ^a   Halfmann, Megan M ^a,c   Maddie, Melissa A ^a,d   Olive, Sarah R ^a,e   Schlachter, Stephen T ^a   Tan, Huiling ^a   Wang, Bin ^a   Wang, Keshi ^a   Xie, Shanhai ^a   Xu, Rui ^a   Yang, Hanbiao ^a   Josey, John A ^a   more..

^a Peloton Therapeutics Inc   (United States)

^b BRISTOL MYERS SQUIBB   (United States)

^c STOWERS INSTITUTE FOR MEDICAL RESEARCH   (United States)

^d Renovo Neural   (United States)

^e Progen Lab   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLIN D1; HYPOXIA INDUCIBLE FACTOR 1ALPHA; HYPOXIA INDUCIBLE FACTOR 1BETA; HYPOXIA INDUCIBLE FACTOR 2ALPHA; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEIN INHIBITOR; PT 2385; SUNITINIB; UNCLASSIFIED DRUG; VASCULOTROPIN A; BASIC HELIX LOOP HELIX TRANSCRIPTION FACTOR; ENDOTHELIAL PAS DOMAIN-CONTAINING PROTEIN 1;

ALLOSTERISM; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CONTROLLED STUDY; CYCLIND1 GENE; DIMERIZATION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG RECEPTOR BINDING; DRUG TOLERABILITY; FEMALE; HUMAN; HUMAN CELL; KIDNEY CARCINOMA; MALE; MOUSE; NONHUMAN; PAI1 GENE; PRIORITY JOURNAL; RAT; SIGNAL TRANSDUCTION; VEGFA GENE; ANIMAL; ANTAGONISTS AND INHIBITORS; CALORIMETRY; CHEMISTRY; DRUG SCREENING; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; KIDNEY TUMOR; PATHOLOGY; POLYMERASE CHAIN REACTION; SCID MOUSE; TUMOR CELL LINE; X RAY CRYSTALLOGRAPHY;

ANIMALS; ANTINEOPLASTIC AGENTS; BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; CALORIMETRY; CARCINOMA, RENAL CELL; CELL LINE, TUMOR; CRYSTALLOGRAPHY, X-RAY; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; KIDNEY NEOPLASMS; MICE; MICE, SCID; POLYMERASE CHAIN REACTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84988983212     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-16-0473     Document Type: Article

References (38)

1. American Cancer Society. Kidney cancer (adult) - renal cell carcinoma. Atlanta, GA: American Cancer Society; 2014.
2. Sosman J, Puzanov I. Combination targeted therapy in advanced renal cell carcinoma. Cancer 2009;115:2368-75.
3. 2 tension. Proc Natl Acad Sci USA 1995;92:5510-14.
4. Tian H, McKnight SL, Russell DW. Endothelial PAS domain protein 1 (EPAS1), a transcription factor selectively expressed in endothelial cells. Genes Dev 1997;11:72-82.
5. Gu YZ, Moran SM, Hogenesch JB, Wartman L, Bradfield CA. Molecular characterization and chromosomal localization of a third alpha-class hypoxia inducible factor subunit, HIF3alpha. Gene Expr 1998;7:205-13.
6. Kaelin WGJr, Ratcliffe PJ. Oxygen sensing bymetazoans: the central role of the HIF hydroxylase pathway. Mol Cell 2008;30:393-402.
7. Majmundar AJ, Wong WJ, Simon MC. Hypoxia-inducible factors and the response to hypoxic stress. Mol Cell 2010;40:294-309.
8. Keith B, Johnson RS, Simon MC. HIF1α and HIF2α: sibling rivalry in hypoxic tumour growth and progression. Nat Rev Cancer 2011;12:9-22.
9. Jaakkola P, Mole DR, Tian YM, Wilson MI, Gielbert J, Gaskell SJ, et al. Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science 2001;292:468-472.
10. Bruick RK, McKnight SL. A conserved family of prolyl-4-hydroxylases that modify HIF. Science 2001;294:1337-40.
11. Sato Y, Yoshizato T, Shiraishi Y, Maekawa S, Okuno Y, Kamura T, et al. Integrated molecular analysis of clear-cell renal cell carcinoma. Nat Genet 2013;45:860-7.
12. Kondo K., Klco J, Nakamura E, Lechpammer M, Kaelin WG Jr. Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein. Cancer Cell 2002;1:237-46.
13. Maranchie JK, Vasselli JR, Riss J, Bonifacino JS, Linehan WM, Klausner RD. The contribution of VHL substrate binding and HIF1-alpha to the phenotype of VHL loss in renal cell carcinoma. Cancer Cell 2002;1:247-55.
14. Kondo K, Kim WY, Lechpammer M, Kaelin WGJr.Inhibition of HIF2alpha is sufficient to suppress pVHL-defective tumor growth. PLoS Biol 2003;1:E83.
15. Zimmer M, Doucette D, Siddiqui N, Iliopoulos O. Inhibition of hypoxia-inducible factor is sufficient for growth suppression of VHL-/- tumors.Mol Cancer Res 2004;2:89-95.
16. Monzon FA, Alvarez K, Peterson L, Truong L, Amato RJ, Hernandez-McClain J, et al. Chromosome 14q loss defines a molecular subtype of clear-cell renal cell carcinoma associated with poor prognosis. Mod Pathol 2011;24:1470-9.
17. Shen C, Beroukhim R, Schumacher SE, Zhou J, Chang M, Signoretti S, et al. Genetic and functional studies implicate HIF1a as a 14q kidney cancer suppressor gene. Cancer Discov 2011;1:222-35.
18. Rogers JL, Bayeh L, Scheuermann TH, Longgood J, Key J, Naidoo J, et al. Development of inhibitors of the PAS-B domain of the HIF-2α transcription factor. J Med Chem 2013;56:1739-47.
19. Scheuermann TH, Li Q, Ma HW, Key J, Zhang L, Chen R, et al. Allosteric inhibition of hypoxia inducible factor-2 with small molecules. Nat Chem Biol 2013;9:271-6.
20. Scheuermann TH, Tomchick DR, Machius M, Guo Y, Bruick RK, Gardner KH. Artificial ligand binding within the HIF2a PAS-B domain of the HIF2 transcription factor. Proc Natl Acad Sci USA 2009;106:450-5.
21. Otwinowski Z, Minor W. Processing of X-ray diffraction data collected in oscillation mode. Methods Enzymol 1997;276:307-26.
22. Emsley P, Cowtan K. Coot: model-building tools for molecular graphics. Acta Crystallogr D Biol Crystallogr 2004;60:2126-32.
23. Murshudov GN, Vagin AA, Dodson EJ. Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallogr D Biol Crystallogr 1997;53:240-55.
24. Key J, Scheuermann TH, Anderson PC, Daggett V, Gardner KH. Principles of ligand binding within a completely buried cavity in HIF2α PAS-B. J Am Chem Soc 2009;132:17647-54.
25. Wu D, Potluri N, Lu J, Kim Y, Rastinejad F. Structural integration in hypoxia-inducible factors. Nature 2015;524:303-8.
26. Gruber M, Hu CJ, Johnson RS, Brown EJ, Keith B, Simon MC. Acute postnatal ablation of Hif-2alpha results in anemia. Proc Natl Acad Sci USA 2007;104:2301-6.
27. Rankin EB, Biju MP, Liu Q, Unger TL, Rha J, Johnson RS, et al. Hypoxia-inducible factor-2 (HIF-2) regulates hepatic erythropoietin in vivo. J Clin Invest 2007;117:1068-77.
28. Nakamura E, Abreu-e-Lima P, Awakura Y, Inoue T, Kamoto T, Ogawa O, et al. Clusterin is a secreted marker for a hypoxia-inducible factor-independent function of the von hippel-lindau tumor suppressor protein.Am J Pathol 2006;168:574-84.
29. Hu C-J, Wang L-Y, Chodosh LA, Keith B, Simon MC. Differential roles of hypoxia-inducible factor 1a (hif-1α) and hif-2α in hypoxic gene regulation. Mol Cell Biol 2003;23:9361-74.
30. Kim WY, Safran M, Buckley MR, Ebert BL, Glickman J, Bosenberg M, et al. Failure to prolyl hydroxylate hypoxia-inducible factor α phenocopies VHL inactivation in vivo. EMBO J 2006;25:4650-62.
31. Sato M, Tanaka T, Maeno T, Sando Y, Suga T, Maeno Y, et al. Inducible expression of endothelial pas domain protein-1 by hypoxia in human lung adenocarcinoma A549 cells role of src family kinases-dependent pathway. Am J Respir Cell Mol Biol 2002;26:127-34.
32. Gordan JD, Lal P, Dondeti VR, Letrero R, Parekh KN, Oquendo CE, et al. HIF-α effects on c-Myc distinguish two subtypes of sporadic VHL-deficient clear cell renal carcinoma. Cancer Cell 2008;14:435-46.
33. Kamba T, McDonald DM. Mechanisms of adverse effects of anti-VEGF therapy for cancer. Br J Cancer 2007;96:1788-1795.
34. Hamnvik OP, Choueiri TK, Turchin A, McKay RR, Goyal L, Davis M, et al. Clinical risk factors for the development of hypertension in patients treated with inhibitors of the VEGF signaling pathway. Cancer 2015;121:311-9.
35. Facemire CS, Nixon AB, Griffiths R, Hurwitz H, Coffman TM. Vascular endothelial growth factor receptor 2 (vegfr2) controls blood pressure by regulating nitric oxide synthase expression. Hypertension 2009;54:652-8.
36. Kappers MHW, van Esch JHM, Sluiter W, Sleijfer S, Danser AHJ, van den Meiracker AH. Hypertension induced by the tyrosine kinase inhibitor sunitinib is associated with increased circulating endothelin-1 levels. Hypertension 2010;56:675-81.
37. Shen C, Kaelin WG. The VHL/HIF axis in clear cell renal carcinoma. Sem Cancer Biol 2013;23:18-25.
38. Jain RK, Duda DG, Clark JW, Loeffler JS. Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nat Clin Pract Oncol 2006;3:24-40.